Small-Cap Stock on Watch: Cell Therapeutics Inc. (CTIC)
  • Stock Report for Cell Therapeutics Inc. (CTIC)
  • Stock Alert for Cell Therapeutics Inc. (CTIC)
  • " />

    Stock Alert for Cell Therapeutics Inc. (CTIC)

    Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of treatments for cancer. The Company focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. CTIC is focused on Pixuvri (pixantrone dimaleate), or Pixuvri, OPAXIO (paclitaxel poliglumex), or OPAXIO, brostallicin and bisplatinates. It is developing a dinuclear-platinum complex. There are three platinates commercially available (cisplatin, carboplatin, and oxaliplatin), which are first-line agents in ovarian cancer, lung cancer, testicular cancer, and colorectal cancer, as well as a range of other diseases. CTIC is developing the dinuclear-platinum complex CT-47463, which has a different mechanism of action than the platinum compounds.
    Share Statistics (28-Sept-11) FY2009 FY2010 % Chg Q22010 Q22011 % Chg
    Symbol CTIC Revenue, $Mn 0.08 0.32 300.0% 0.30 0.00 -100.0%
    Current price $1.04 Gross marg. 100.0% 100.0% 0.0% 100.0%
    52wk Range: $0.95-$3.30 Oper. margin -23479.6%
    Avg Vol (3m): 1,814,010 Net margin -119237.5% -25825% -78.3% -7826.7%
    Market Cap. 200.59M
    Shares Outstanding 192.88M EPS, $ -1.55 -1.29 -16.8% -0.48 -0.14 -70.8%

    Source:, SEC Filings.

    Investment Highlights

    Shares of CTIC have gained 7.9% in the last five days, though the stock lost 3.5% in the last month. Year-to-date, the stock is down 51.0%.

    Share of CTIC jumped as much as 8% on Wednesday after the Company said a second independent radiology assessment of data from a clinical trial of its antitumor treatment pixantrone confirmed the statistical robustness of the data. The response and progression endpoint data was previously submitted to the U.S. Food and Drug Administration (FDA) with the new drug application (NDA) for pixantrone.

    The Seattle, Washington-based cancer drug developer said in the press release that the second assessment was recommended by the FDA’s Office of New Drugs as part of the Company’s appeal of the Complete Response Letter for the NDA, which CTIC received from the FDA’s Office of Oncology Drug Products.

    “We now have two separate independent response assessment panels reporting significant results for complete response/complete response unconfirmed, overall response rate and progression-free survival at both end of treatment and end of study assessment periods as well as among the histologically confirmed aggressive non-Hodgkin’s lymphoma (NHL) subset of patients,” commented James A. Bianco M.D., CEO of CTIC.

    CTIC said it plans on resubmitting the pixantrone NDA as early as October 2011 for accelerated approval.

    The Division of Oncology Drug Products (DODP) previously confirmed that the review of the NDA would be completed within six months from the date of resubmission, which should provide CTIC an FDA action date by April 2012.

    CTIC hit an intra-day high of $1.19 but dropped later in the session to close at $1.04, down 5.45% from the previous close.  Over the past 52 week, the stock has been trading in the range of $0.95 – $3.30.  Nearly 2.6 million shares traded hands during the session, compared to the 10-day average of 1.4 million.


    Financial Summary

    CTIC reported total operating expenses of $16.9 million for the second quarter ended June 30, 2011, down 15% from $20.0 million reported in the same period last year.  The Company reported no revenues for the latest quarter.

    Net loss attributable to common shareholders for the quarter came in at $22.5 million, or $0.14 per share, down 58% from the year-ago figure of $53.6 million, or $0.48 per share. The Company attributed the decrease to lower operating expenses and lower deemed non-cash dividends on preferred stock issuances.

    CTIC had approximately $38.9 million in cash and cash equivalents as of June 30, 2011, including $5.8 million of partially received funds in a $30 million equity offering which closed in July 2011.


    Financial Strength (28-Sept-2011)




    S&P 500

    Quick Ratio (MRQ) 2.82 1.76 0.77
    Current Ratio (MRQ) 1.16 3.40 2.17 1.13
    LT Debt to Equity (MRQ) 99.34 15.31 23.86 109.49
    Total Debt to Equity (MRQ) 503.92 17.90 30.29 146.76
    Interest Coverage (TTM) -20.42 18.12 1.66 24.11

    Source:, SEC Filings.

    Technical Analysis



    CTIC’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Sept28-2011 symbol Share, $ $ Mn 2011 2012 2011 2012
    Bristol-Myers Squibb Company BMY 30.84 52.60B 13.53 14.97 2.49 2.88
    Sanofi-Aventis SNY 33.05 88.72B 6.91 7.41 1.83 1.77
    Biotechnology Median       18.15 n/a 9.41 n/a
    Cell Therapeutics Inc. CTIC 1.04 200.59M n/a n/a n/a 3.52

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *